Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support in cancer patients with Major Depressive Disorder (MDD) is out.
Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session
